Delayed gastric emptying and enteric nervous system dysfunction in the rotenone model of Parkinson's disease.
Gastrointestinal (GI) dysfunction is the most common non-motor symptom of Parkinson's disease (PD). Symptoms of GI dysmotility in PD include early satiety and weight loss from delayed gastric emptying and constipation from impaired colonic transit. Understanding the pathophysiology and treatment of these symptoms in PD patients has been hampered by the lack of investigation into GI symptoms and pathology in PD animal models. We report that the parkinsonian neurotoxin and mitochondrial complex I inhibitor rotenone causes delayed gastric emptying and enteric neuronal dysfunction when administered chronically to rats in the absence of major motor dysfunction or CNS pathology. When examined 22-28 days after initiation of rotenone infusion by osmotic minipump (3 mg/kg/day), 45% of rotenone-treated rats had a profound delay in gastric emptying. Electrophysiological recording of neurally-mediated muscle contraction in isolated colon from rotenone-treated animals confirmed an enteric inhibitory defect associated with rotenone treatment. Rotenone also induced a transient decrease in stool frequency that was associated with weight loss and decreased food and water intake. Pathologically, no alterations in enteric neuron numbers or morphology were apparent in rotenone-treated animals. These results suggest that enteric inhibitory neurons may be particularly vulnerable to the effects of mitochondrial inhibition by parkinsonian neurotoxins and provide evidence that parkinsonian gastrointestinal abnormalities can be modeled in rodents.
Greene
James G
JG
Department of Neurology, Emory University School of Medicine, 505H Whitehead Biomedical Research Bldg, 615 Michael St, Atlanta, GA 30322, USA. james.greene@emory.edu
Noorian
Ali Reza
AR
Srinivasan
Shanthi
S
D000704:Analysis of Variance; D000818:Animals; D001522:Behavior, Animal; D001921:Brain / Q000473:pathology; D002452:Cell Count / Q000379:methods; D004195:Disease Models, Animal; D051959:ELAV Proteins / Q000378:metabolism; D017615:Enteric Nervous System / Q000473:pathology / Q000503:physiopathology*; D005746:Gastric Emptying / Q000187:drug effects* / Q000502:physiology; D005769:Gastrointestinal Motility / Q000187:drug effects; D007537:Isometric Contraction / Q000187:drug effects; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D009130:Muscle, Smooth / Q000187:drug effects / Q000503:physiopathology; D009474:Neurons / Q000187:drug effects / Q000502:physiology; D010302:Parkinson Disease, Secondary / Q000139:chemically induced* / Q000150:complications*; D051381:Rats; D011917:Rats, Inbred Lew; D012402:Rotenone; D013272:Stomach Diseases / Q000209:etiology*; D013997:Time Factors; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism
D051959:ELAV Proteins; D012402:Rotenone; D014446:Tyrosine 3-Monooxygenase